MedTrace Logo

Role of Suppression of Endometriosis With Progestins Before IVF-ET

NCT04500743 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2020-08-05

No results posted yet for this study

Summary

This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment.

Conditions

  • IVF
  • Endometriosis
  • Pregnancy Rate
  • Progestins
  • GnRH-analogue

Interventions

DRUG

Dienogest

Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF

DRUG

leuprorelin acetate

Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)

Sponsors & Collaborators

  • National Research Centre, Egypt

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-10-31
Completion
2020-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04500743 on ClinicalTrials.gov